Sei Investments Co. Has $964,000 Stock Holdings in Rapport Therapeutics, Inc. $RAPP

Sei Investments Co. raised its holdings in Rapport Therapeutics, Inc. (NASDAQ:RAPP) by 68.7% during the first quarter, Holdings Channel reports. The institutional investor owned 30,819 shares of the company’s stock after buying an additional 12,551 shares during the quarter. Sei Investments Co.’s holdings in Rapport Therapeutics were worth $964,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Rapport Therapeutics by 86.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after acquiring an additional 4,582 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC bought a new position in Rapport Therapeutics in the 1st quarter valued at about $2,039,000. Rhumbline Advisers lifted its position in Rapport Therapeutics by 40.1% in the 1st quarter. Rhumbline Advisers now owns 14,358 shares of the company’s stock valued at $144,000 after acquiring an additional 4,109 shares in the last quarter. Geode Capital Management LLC boosted its stake in Rapport Therapeutics by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 333,159 shares of the company’s stock valued at $3,789,000 after purchasing an additional 17,496 shares during the last quarter. Finally, Creative Planning acquired a new position in Rapport Therapeutics during the 2nd quarter valued at about $121,000.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Leerink Partners started coverage on Rapport Therapeutics in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $52.00 price objective for the company. William Blair began coverage on Rapport Therapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Friday, July 17th. HC Wainwright increased their price target on Rapport Therapeutics from $40.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, BTIG Research reissued a “buy” rating and issued a $65.00 price target on shares of Rapport Therapeutics in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $61.57.

Insider Activity at Rapport Therapeutics

In related news, CEO Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the sale, the chief executive officer directly owned 486,108 shares in the company, valued at approximately $23,338,045.08. This trade represents a 5.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $40.05, for a total value of $743,808.60. Following the completion of the transaction, the insider directly owned 6,280,525 shares in the company, valued at approximately $251,535,026.25. This represents a 0.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 72,281 shares of company stock valued at $3,269,892. 12.48% of the stock is currently owned by corporate insiders.

Rapport Therapeutics Stock Performance

Rapport Therapeutics stock opened at $47.73 on Thursday. Rapport Therapeutics, Inc. has a fifty-two week low of $13.86 and a fifty-two week high of $49.50. The firm’s 50-day simple moving average is $40.46 and its 200 day simple moving average is $35.05. The stock has a market cap of $2.29 billion, a PE ratio of -15.70 and a beta of 0.97.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, analysts predict that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Rapport Therapeutics Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.